Cover Image
市場調查報告書

腫瘤壞死因子受體超級家族成員6:開發中產品分析

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 368712
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤壞死因子受體超級家族成員6:開發中產品分析 Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H1 2018
出版日期: 2018年05月08日 內容資訊: 英文 42 Pages
簡介

本報告提供以腫瘤壞死因子受體超級家族成員6為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

腫瘤壞死因子受體超級家族成員6 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • G&E Herbal Biotechnology Co., Ltd.
  • KAHR medical Ltd.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1444TDB

Summary

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) pipeline Target constitutes close to 6 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein encoded by the TNFRSF6 gene. It acts as a receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of mature T-cells. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively.

Report covers products from therapy areas Oncology, Immunology, Ophthalmology, Central Nervous System, Dermatology and Infectious Disease which include indications Autoimmune Disorders, Retinal Pigment Epithelial (RPE) Detachment, Actinic (Solar) Keratosis, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Genital Warts (Condylomata Acuminata), Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Ovarian Cancer, Transplant Rejection, Warts and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Overview 6
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Development 7
  • Products under Development by Stage of Development 7
  • Products under Development by Therapy Area 8
  • Products under Development by Indication 9
  • Products under Development by Companies 10
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Assessment 12
  • Assessment by Mechanism of Action 12
  • Assessment by Route of Administration 14
  • Assessment by Molecule Type 16
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Companies Involved in Therapeutics Development 18
  • Baliopharm AG 18
  • G&E Herbal Biotechnology Co Ltd 18
  • KAHR medical Ltd 19
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Drug Profiles 20
  • APO-010 - Drug Profile 20
  • Product Description 20
  • Mechanism Of Action 20
  • R&D Progress 20
  • KAHR-102 - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • Novotarg - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • ONL-101 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • ONL-1204 - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • SRT-100 - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Dormant Products 31
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Product Development Milestones 33
  • Featured News & Press Releases 33
  • May 31, 2017: MPI's spinout Oncology Venture's second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug 33
  • May 31, 2017: OV's second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug 33
  • Mar 28, 2017: ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team 33
  • Mar 21, 2017: ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program 35
  • Oct 07, 2016: All four Danish centers have started screening Multiple Myeloma patients for OV's APO010 Study 35
  • Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV's APO010 Study 36
  • Mar 10, 2016: First Patient Included In APO010 Immuno-Oncology Screening Trial By MPI's Spinout Oncology Venture 36
  • Feb 11, 2016: ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment from FDA 37
  • Jun 15, 2015: ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases 37
  • May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA 38
  • Dec 16, 2014: KAHR Medical receives government grant sum of 8.2 M Shekels approved by the Chief Scientist Office 38
  • Nov 12, 2014: ONL Therapeutics Receives Phase II SBIR Grant From National Eye Institute for Development of Novel Retinal Disease Treatment 39
  • Dec 24, 2013: KAHR Medical to Receive NIS 4 million (over $1.1 million USD) in Additional Government Grants 40
  • Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 40
  • May 09, 2012: Baliopharm Signs Licensing Agreement For The Development Of A Bispecific Antibody Indicated For The Treatment Of Cancer And Inflammatory Diseases. 40
  • Appendix 41
  • Methodology 41
  • Coverage 41
  • Secondary Research 41
  • Primary Research 41
  • Expert Panel Validation 41
  • Contact Us 41
  • Disclaimer 42

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018 7
  • Number of Products under Development by Therapy Areas, H1 2018 8
  • Number of Products under Development by Indication, H1 2018 9
  • Number of Products under Development by Companies, H1 2018 10
  • Products under Development by Companies, H1 2018 11
  • Number of Products by Stage and Mechanism of Actions, H1 2018 13
  • Number of Products by Stage and Route of Administration, H1 2018 15
  • Number of Products by Stage and Molecule Type, H1 2018 17
  • Pipeline by Baliopharm AG, H1 2018 18
  • Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2018 18
  • Pipeline by KAHR medical Ltd, H1 2018 19
  • Dormant Products, H1 2018 31
  • Dormant Products, H1 2018 (Contd..1), H1 2018 32

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018 7
  • Number of Products under Development by Therapy Areas, H1 2018 8
  • Number of Products under Development by Top 10 Indications, H1 2018 9
  • Number of Products by Mechanism of Actions, H1 2018 12
  • Number of Products by Stage and Mechanism of Actions, H1 2018 12
  • Number of Products by Routes of Administration, H1 2018 14
  • Number of Products by Stage and Routes of Administration, H1 2018 14
  • Number of Products by Molecule Types, H1 2018 16
  • Number of Products by Stage and Molecule Types, H1 2018 16
Back to Top